Clinical Trial Update: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating immunogenicity and safety of a tetravalent dengue vaccine booster in adults who completed a 3-dose schedule; results completed a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever
• Dengue Hemorrhagic Fever

Drugs mentioned

• Tetravalent dengue vaccine (Sanofi Pasteur) (unspecified tetravalent dengue vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Status: COMPLETED | Results posted: 2019-06-14